コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 testinal macrophages and dendritic cells via toll like receptor 4.
2 s, an event triggered by the innate receptor Toll-like receptor 4.
3 lowing binding of growth factor receptors or Toll-like receptor 4.
4 ccharides through Toll-like receptors, e.g., Toll-like receptor 4.
5 dapter molecule 1, toll-like receptor 2, and toll-like receptor 4.
6 nflammation in ALD through activation of the Toll-like receptor 4.
7 stic cells by anticardiolipin occurs through Toll-like receptor 4.
8 nism remarkably similar to that of mammalian Toll-like Receptor 4.
9 nd to enhance fibroblast CCN2 expression via Toll-like receptor 4.
10 f IL-1R8, diminishing activation mediated by toll-like receptor 4.
11 to Kupffer cells (KCs) and co-localized with toll-like receptor 4.
12 to 10 days and is partially mediated through toll-like receptor 4.
13 ter wall of Gram-negative bacteria, with the Toll-like Receptor 4.
14 eta1 integrin and the innate immune receptor toll-like receptor 4.
15 ury triggering the macrophage activation via Toll-like receptor 4.
16 s blunted by incubation with an inhibitor of Toll-like receptor 4.
18 60 adjuvanted with nanoparticle-encapsulated Toll-like receptor 4/7/8 (TLR4/7/8) agonists, administer
19 Chemical inhibition or genetic deletion of Toll-like receptor 4, a pattern recognition receptor res
20 t PTX sensitizes mice to HA independently of Toll-like receptor 4, a purported receptor for PTX, and
21 otein (CRP) at baseline and months 4 and 16; toll-like receptor-4 activated monocyte production of pr
24 ts demonstrate that the use of the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A in s
25 ated the immune response elicited by a novel Toll-like receptor 4 agonist vaccine adjuvant, glucopyra
26 with glucopyranosyl lipid adjuvant (GLA), a Toll-like receptor 4 agonist, in a squalene-in-water emu
27 s pathway, and monophosphoryl lipid A, and a Toll-like receptor 4 agonist, which synergize to produce
30 ses both in vivo and in vitro LPS stimulates Toll-like receptor 4, an important mediator of the brain
31 reduced lipopolysaccharide activation of the toll-like receptor 4 and increased survival times compar
32 astrocytic GAP43 expression was mediated by Toll-like receptor 4 and nuclear factor-kappaB (NF-kappa
34 nflammatory factors including TNFalpha via a Toll-like receptor 4 and STAT3-dependent mechanism in hu
36 identified two innate immune cell receptors, Toll-like receptor 4 and type 1 interferon receptor (IFN
40 on of IL-33 in DCs is dependent on FcRgamma, Toll-like receptor 4, and phosphoinositide 3-kinase.
41 so improved the level of HA receptors (CD44, Toll-like receptor-4, and receptor for HA-mediated motil
44 ube and network formation in the presence of Toll-like receptor 4 blockade but not in the presence of
46 ood monocytes and 30% lower monocyte surface Toll-like receptor 4, compared with those with high expr
47 ts a strong host immune response through the Toll-like receptor 4 complex, and acts as a component of
48 in their livers and spleens for months, but Toll-like receptor 4-deficient animals succumbed to thes
49 failed to induce depressive-like behavior in Toll-like receptor 4-deficient mice and in mice harborin
50 RI had increased disulfide-HMGB1 and induced Toll-like receptor 4-dependent tumor necrosis factor alp
51 ll-derived Fn-EDA exacerbates stroke through Toll-like receptor-4 expressed on hematopoietic cells.
52 with healthy controls (p = 0.0002), whereas Toll-like receptor 4 expression was decreased compared w
53 evated hepatic stellate cell-derived TnC and Toll-like receptor 4 expression was observed in the diet
58 show that upon cancer-induced activation of Toll-like receptor 4 in skeletal muscle, p38beta MAPK ph
61 nate antimicrobial responses was observed in toll-like receptor 4 knockout mice treated with 3-deacyl
62 ter P. aeruginosa infection in wild-type and toll-like receptor 4 knockout mice treated with 3-deacyl
63 ity to inhibit lipopolysaccharide binding to toll-like receptor-4, leading to reductions in mitogen-a
64 f mice with either protein formulated with a Toll-like receptor 4 ligand (TLR4L)-containing adjuvant
65 effect of liver inflammation induced by the Toll-like receptor 4 ligand lipopolysaccharide (LPS) wit
68 They share regulatory function downstream of Toll-like receptor 4/LPS in mast cells, through regulati
70 and subsequent sustained bacteremia leads to Toll-like receptor 4-mediated hyperinflammation and leth
71 rass pollen or mite allergens to enhance the Toll-like receptor 4-mediated proallergic properties of
74 d antagonizing the activation of LPS-induced Toll-like receptor 4-myeloid differentiation factor 2 (T
75 entially detected by host receptors like the Toll-like receptor 4/myeloid differentiation factor 2 co
77 ediated by the cluster of differentiation 14/Toll-like receptor 4/myeloid differentiation protein 2 (
78 ly inhibited lipopolysaccharide binding to a toll-like receptor-4/myeloid differentiation factor 2 fu
80 ation by the innate immune system, including Toll-like receptor 4, nuclear factor kappa-light-chain-e
81 and bicarbonate secretion, up-regulation of toll-like receptor 4/nuclear factor kappa light-chain-en
83 Inhibition of PKR or NE or neutralization of Toll-like receptor 4 or 2(TLR4 or TLR2) prevented the de
84 nd SseK3 suppress TNF-alpha-induced, but not Toll-like receptor 4- or interleukin-induced, NF-kappaB
87 tion of MMP-1 and COX-2 was mediated through Toll-like receptor-4, possibly through thrombin-induced
88 mechanisms by which inflammation - driven by Toll-like receptor 4-regulated cytokines, immune cells a
89 l a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in bili
90 ine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear
94 arly postnatal inflammatory stimuli activate toll-like receptor 4 signaling in astrocytes and promote
96 ng low-status-associated polarization of the Toll-like receptor 4 signaling pathway toward a proinfla
99 nown that lipopolysaccharide (LPS)-activated toll-like receptor 4 signaling pathways play a crucial r
100 d an innate immune response by activation of Toll-like receptor 4 signaling to MD2 and CD14, and caus
101 lls, relied on innate immune sensing through toll-like receptor 4 signaling, and ultimately depended
102 gram-negative bacterial products in situ via Toll-like receptor 4 signaling, contributing to genital
106 es of TAK-242, a small molecule inhibitor of Toll-like receptor 4, that primarily reacted with a sing
108 fter infection with Y. pestis, influenced by Toll-like receptor 4-TIR-domain-containing adapter-induc
109 NA levels were assessed by real-time PCR and Toll like receptor 4 (TLR-4) protein expression by Weste
110 t into atherosclerotic lesions and inhibited toll-like receptor 4 (TLR 4)-initiated proinflammatory m
111 the present study is to examine the level of Toll-like receptor 4 (TLR-4), interleukin-18 (IL-18), an
112 increase in TJ permeability was mediated by toll-like receptor 4 (TLR-4)/MyD88 signal-transduction p
114 livery system, and simultaneously, activated Toll-Like Receptor-4 (TLR-4) on APCs to release chemokin
116 different human-compatible adjuvants (alum, Toll-like receptor 4 [TLR-4] agonist glucopyranosal lipi
120 ng number of pathologies have been linked to Toll-like receptor 4 (TLR4) activation and signaling, th
123 ponses of macrophages and dendritic cells to Toll-like receptor 4 (TLR4) activation induced by lipopo
124 nd mRNA translation lead to hypothesize that toll-like receptor 4 (TLR4) activation reduced LNP-media
126 DM), which is similar to that induced by the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide.
127 immune stimulation, such as treatment with a Toll-like receptor 4 (TLR4) agonist, enhanced bacterial
129 g stimulation by lipopolysaccharide (LPS) of Toll-like receptor 4 (TLR4) and by poly(I.C) of TLR3 but
130 iated mainly by leukocytes that express both Toll-like receptor 4 (TLR4) and Fc gamma receptors (Fcga
131 e microbiota, hematopoietic cell deletion of Toll-like receptor 4 (TLR4) and inactivation of the IL-1
132 with a decrease in the expression of mucosal toll-like receptor 4 (TLR4) and its adaptor myeloid diff
133 LPS-induced ACSL1 expression is dependent on Toll-like receptor 4 (TLR4) and its adaptor protein TRIF
134 ring P rats have innately elevated levels of Toll-like receptor 4 (TLR4) and monocyte chemotactic pro
135 rcentages and sputum cell gene expression of Toll-like receptor 4 (TLR4) and NLRP3 at 4 hours in nono
136 emic low-dose morphine (LDM) share action at Toll-like receptor 4 (TLR4) and signaling via protein ki
137 hat expression of the innate immune receptor Toll-like receptor 4 (TLR4) and the extracellular matrix
139 f innate immune signaling systems, including toll-like receptor 4 (TLR4) and the interleukin-1beta (I
140 the combination of synthetic small-molecule Toll-like receptor 4 (TLR4) and TLR7 ligands is a potent
141 show here that the combination of synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands is a potent
143 ntigens adjuvanted with ligands specific for Toll-like receptor 4 (TLR4) and TLR7/8 encapsulated in p
145 The results point to modified signaling via Toll-like receptor 4 (TLR4) as a possible mechanism for
146 further implicate the innate immune receptor toll-like receptor 4 (TLR4) as an underlying mechanism m
148 Recognition of lipopolysaccharides (LPS) by Toll-like receptor 4 (TLR4) at the plasma membrane trigg
152 evels of NF-kappaB in human embryonic kidney Toll-like receptor 4 (TLR4) cells and murine embryonic f
154 ined to be associated with downregulation of Toll-like receptor 4 (TLR4) expression on the surface of
156 L1 as a critical structural component of the Toll-like receptor 4 (TLR4) immune signal transduction p
157 Ps) induced NF-kappaB activation mediated by Toll-like receptor 4 (TLR4) in a glycoprotein (GP)-depen
158 MA with wild-type lipid A to stimulate human Toll-like receptor 4 (TLR4) in a reporter cell line.
160 Increasing evidence points to a key role for toll-like receptor 4 (TLR4) in chronic pain states of so
162 ing studies indicate a sex-dimorphic role of Toll-like receptor 4 (TLR4) in driving neuropathic pain.
163 m gene knockout studies supports the role of Toll-like receptor 4 (TLR4) in intestinal inflammation a
166 cal role for the lipopolysaccharide receptor toll-like receptor 4 (TLR4) in NEC development through i
167 s, we first evaluated the role of nociceptor Toll-like receptor 4 (TLR4) in OIH and priming induced b
169 tumor necrosis factor-alpha (TNFalpha), and Toll-like receptor 4 (TLR4) in surgically excised specim
170 critical role of innate immune signaling via Toll-like receptor 4 (TLR4) in the pathogenesis of dyspl
173 Our findings demonstrate that LPS induces Toll-like receptor 4 (TLR4) internalization in corneal e
178 tirely clear, current evidence suggests that Toll-like receptor 4 (TLR4) is a key player in the mecha
186 n enhanced sensitivity of macrophages to the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (L
187 We investigated the role of an endogenous Toll-like receptor 4 (TLR4) ligand, fibronectin-EDA (FN-
188 morphine binds to the innate immune receptor toll-like receptor 4 (TLR4) localized primarily on micro
191 xamined the effect of innate immune receptor Toll-like receptor 4 (TLR4) on excitability of the hippo
192 ed by a paracrine mechanism that engaged the Toll-like receptor 4 (TLR4) on hair cells to protect the
193 eria activates plasma membrane signaling via Toll-like receptor 4 (TLR4) on host cells and triggers i
194 mponents such as lipopolysaccharide (LPS) by Toll-like receptor 4 (TLR4) on macrophages induces a rob
197 ow that GOS is recognized by and upregulates Toll-like receptor 4 (TLR4) on RAW264.7 macrophages, fol
198 either bacterial lipopolysaccharide through Toll-like receptor 4 (TLR4) or leukocyte cytokine IFN-ga
200 interacts with rapid kinetics to engage the Toll-like receptor 4 (TLR4) pathway, leading to the prod
202 tumor necrosis factor alpha (TNF-alpha) and Toll-like receptor 4 (TLR4) pathways, and resulted in co
203 entiation revealed that binding of S100A9 to Toll-like receptor 4 (TLR4) promotes activation of p38 m
206 driven by microbial-dependent activation of toll-like receptor 4 (TLR4) signaling and subsequent eng
208 recently discovered the presence of multiple Toll-like receptor 4 (TLR4) signaling intermediates in l
212 -TOF MS), gas chromatography (GC), SDS-PAGE, Toll-like receptor 4 (TLR4) stimulation, and immunoblot
213 re, we provide evidence that immune receptor toll-like receptor 4 (TLR4) supports OL lineage cell spa
214 emonstrate that hRetn binds the LPS receptor Toll-like receptor 4 (TLR4) through its N terminal and m
217 that ragweed pollen extract (RWPE) requires Toll-like receptor 4 (TLR4) to stimulate CXCL-mediated i
218 ced by reduced proinflammatory responses via Toll-like receptor 4 (TLR4) to the hypoacylated LPS.
219 ent of Gram-negative bacteria that activates Toll-like receptor 4 (TLR4) to trigger proinflammatory r
220 300b, and its adaptor DAP12, associated with Toll-like receptor 4 (TLR4) upon LPS binding, thereby en
223 osis factor alpha (TNF-alpha) or blocking of Toll-like receptor 4 (TLR4), (v) was absent in TLR4-knoc
224 as a consequence of sequential activation of toll-like receptor 4 (TLR4), a receptor for endotoxin, a
225 data suggest that the innate immune receptor Toll-like receptor 4 (TLR4), along with its coreceptor m
227 -NS5A in liver up-regulate the expression of Toll-like receptor 4 (TLR4), and develop liver tumors co
228 hat can lyse bacteria, suppress signaling by Toll-like receptor 4 (TLR4), and enhance signaling to do
229 of normal human monocytes, primarily through Toll-like receptor 4 (TLR4), and suppressed phytohemaggl
230 o found to bind TRAM, an adaptor protein for Toll-like receptor 4 (TLR4), and thereby impact both vir
231 nses invoked by IL-1beta, TNF-alpha, and LPS/Toll-like receptor 4 (TLR4), but not TRIF-dependent poly
233 d not require T-cell-intrinsic expression of toll-like receptor 4 (TLR4), interleukin-1 receptor (IL-
234 ith the immunosurveillance receptor complex, Toll-like receptor 4 (TLR4), on microglial cells to init
235 ytoplasm and downregulated the expression of toll-like receptor 4 (TLR4), receptor for advanced glyca
236 s can be induced by endotoxin stimulation of Toll-like receptor 4 (TLR4), resulting in an ameliorated
237 conditions were previously found to activate Toll-like receptor 4 (TLR4), resulting in expression of
238 with lipopolysaccharide (LPS), the ligand of Toll-like receptor 4 (TLR4), reveals previously unobserv
239 ssociated lipopolysaccharide (LPS) activates Toll-like receptor 4 (TLR4), stimulating production of t
241 gle study revealed a new complex composed of Toll-like receptor 4 (TLR4), TLR6, and CD36 induced by f
243 ediated activation of TRPC1 was dependent on Toll-like receptor 4 (TLR4), which induced endoplasmic r
244 einphagy requires the presence of microglial Toll-like receptor 4 (TLR4), which induces transcription
245 Bile duct cells expressed the LPS receptor, Toll-like receptor 4 (TLR4), which links to activation o
246 olecules and innate immune receptors such as Toll-like receptor 4 (TLR4), which recognizes the lipid
247 sma G-CSF levels and neutrophil numbers in a Toll-like receptor 4 (TLR4)- and myeloid differentiation
248 del of PHH, we demonstrate that IVH causes a Toll-like receptor 4 (TLR4)- and NF-kappaB-dependent inf
251 one was sufficient to induce meningitis in a Toll-like receptor 4 (TLR4)-CXCL2-dependent manner.
252 production by modulating host immunity in a Toll-like receptor 4 (TLR4)-dependent manner, a signalin
255 EL induced PTX3 expression by activating the Toll-like receptor 4 (TLR4)-dependent pathway via nuclea
257 ct ligations or sham surgeries on C57BL/6 or toll-like receptor 4 (TLR4)-knockout mice to induce live
258 in LPS activates innate immunity through the Toll-like receptor 4 (TLR4)-MD-2 complex on host cells.
260 ages involves multiple mechanisms, including Toll-like receptor 4 (TLR4)-mediated NADPH oxidase (NOX)
261 f opioids, and we recently demonstrated that Toll-like receptor 4 (TLR4)-mediated neuroinflammation i
263 ue damage and expressed by tumors, activates toll-like receptor 4 (TLR4)-mediated sterile inflammatio
264 pid Lipid A, initiates the activation of the Toll-like Receptor 4 (TLR4)-myeloid differentiation fact
276 these cytokines during bacterial sepsis via Toll-like receptor 4 (TLR4)/MyD88 sensing of lipopolysac
279 A3 are transcriptional targets of S100A4 via Toll-like receptor 4 (TLR4)/nuclear factor-kappaB signal
281 tor cluster-of-differentiation 14 (CD14) and Toll-like receptor 4 (TLR4; essential for the LPS respon
282 cyte-specific deletion of YAP (YAP( KO) ) or Toll-like receptor 4 (TLR4; TLR4( KO) ), and animals wer
283 In mechanistic experiments, inhibition of toll-like receptor-4 (TLR4) and the receptor for advance
285 the present study was to assess the role of Toll-like receptor-4 (TLR4) in mediating the inflammator
287 of this process, inducing the activation of toll-like receptor-4 (TLR4) signaling and endoplasmic re
289 ene Expression Array Plates system for genes Toll-like receptor-4 (TLR4), high-mobility group box 1,
293 5) increased hypothalamic microglia density, toll-like-receptor-4 (Tlr4), and the inhibitor-NF-kappa-
294 resistant to Fas-mediated apoptosis ex vivo, Toll-like receptor 4(TLR4)-ligation restored Fas-sensiti
295 Thus, TRIF signaling (likely downstream of Toll-like receptor 4, TLR4) serves as one of the microbi
296 Activation of ERK signaling, downstream of toll-like receptor 4, was essential to the mitogenic eff
298 also attenuated proinflammatory signaling by Toll-like receptor 4, which has a central role in Ad pat
299 A member of the toll-like receptor family, toll-like receptor 4, which is known to contribute to di
300 d macrophages (BMDM) upon stimulation of the Toll-like receptor 4 with Kdo2-Lipid A (KLA) and stimula